Repligen Corporation ($RGEN) Stock Forecast: Down 5.2% Today

What is Repligen Corporation?

Repligen Corporation (RGEN) is a biotechnology company that specializes in providing products and solutions for the biopharmaceutical industry. The company has recently exceeded earnings expectations and shown strong financial performance.

Why is Repligen Corporation going down?

RGEN stock is down 5.2% on Mar 12, 2026 16:15

• The bearish movement in RGEN's stock today could be attributed to concerns about potential valuation risks due to its high P/E ratio of 138x, significantly above the industry average.
• Despite the positive financial performance and exceeding earnings expectations, the pressure faced by healthcare stocks after a weak February jobs report might have contributed to the downward movement in RGEN's stock price.
• The increased stake by institutional investors like Geneva Capital Management LLC and Schroder Investment Management Group could indicate a vote of confidence in the company's long-term prospects, potentially mitigating some of the short-term bearish sentiment.
• Investors may be reevaluating RGEN's valuation and growth prospects in light of mixed sentiment and the need to carefully analyze the company's financial numbers amidst market uncertainties.

RGEN Price Chart

RGEN Technical Analysis

RGEN News

Biological Product IgG Purification Medium Market Is Going to Boom | Repligen Corporation • Agilent Technologies

The Biological Product IgG Purification Medium Market is projected to see substantial growth from 2026 to 2033, driven by increasing demand and innovation. A new report by Coherent Market Insights provides a deep dive into market trends, competitive landscapes, and growth opportunities, offering essential insights for industry leaders. Key players include Thermo Fisher Scientific, Merck KGaA, and Repligen Corporation.

https://www.openpr.com/news/4421743/biological-product-igg-purification-medium-market-is-going

Repligen Corporation $RGEN Shares Purchased by Geneva Capital Management LLC

Geneva Capital Management LLC significantly increased its stake in Repligen Corporation (RGEN) by 22.4% in Q3, now holding 596,768 shares valued at approximately $79.8 million. The biotechnology company recently exceeded earnings expectations, reporting Q3 EPS of $0.49 and revenue of $197.9 million, while analysts have a "Moderate Buy" consensus rating with a target price of $174.58.

https://www.marketbeat.com/instant-alerts/filing-repligen-corporation-rgen-shares-purchased-by-geneva-capital-management-llc-2026-03-11/

Schroder Investment Management Group Purchases 254,212 Shares of Repligen Corporation $RGEN

Schroder Investment Management Group significantly increased its stake in Repligen Corporation (NASDAQ:RGEN) by 123.2% in the third quarter, acquiring 254,212 additional shares to own a total of 460,609 shares valued at $61.57 million. This move highlights continued institutional interest in Repligen, with hedge funds and other institutional investors now owning 97.64% of the stock. Despite mixed analyst sentiment, Repligen has shown strong financial performance, beating quarterly expectations and projecting optimistic FY2026 guidance.

https://www.marketbeat.com/instant-alerts/filing-schroder-investment-management-group-purchases-254212-shares-of-repligen-corporation-rgen-2026-03-11/

(RGEN) Risk Channels and Responsive Allocation

This article provides an analysis of Repligen Corporation (NASDAQ: RGEN), highlighting weak near and mid-term sentiment but a strong long-term outlook. It details three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis, and offers access to real-time signals and customized risk models.

https://news.stocktradersdaily.com/news_release/23/RGEN_Risk_Channels_and_Responsive_Allocation_031026034001_1773128401.html

Reassessing Repligen (RGEN) Valuation After Healthcare Jobs Shock And Margin Concerns

Repligen (RGEN) is facing pressure after a weak February jobs report impacted healthcare stocks, despite reporting positive revenue and net income for Q4 and full-year 2025. While a popular valuation narrative suggests the stock is undervalued at $190.89 compared to its current $119.99, its high P/E ratio of 138x, significantly higher than the industry average, indicates potential valuation risk. Investors are urged to examine the numbers carefully despite mixed sentiment regarding the company's future growth and valuation.

https://www.sahmcapital.com/news/content/reassessing-repligen-rgen-valuation-after-healthcare-jobs-shock-and-margin-concerns-2026-03-08

Trending Today

Ethereum ($ETH) Crypto Forecast: Down 5.5% Today

Dogecoin ($DOGE) Crypto Forecast: Down 5.3% Today

Repligen Corporation Price History

14.00.2026 - RGEN Stock was down 5.1%

• AI models analyzing RGEN suggest choppy conditions and conflicting sentiment across various time horizons.
• Institutional trading strategies suggest positions, momentum breakouts, and risk hedging with specified entry, target, and stop-loss levels.
• Multi-timeframe signal strengths, support, and resistance levels paint a challenging outlook for RGEN in the near-term, mid-term, and long-term.
• The bearish movement in RGEN's stock price is possibly due to the choppy market conditions and conflicting sentiment identified in the AI analysis, which have led to heightened selling pressure and a downward trend in the stock.

11.02.2026 - RGEN Stock was down 5.2%

• The bearish movement in RGEN's stock today could be attributed to concerns regarding declining operating margins and reduced return on invested capital, despite the company's improved earnings report.
• The participation of Repligen Corporation in upcoming investor conferences may have failed to reassure investors about the company's growth potential, leading to a negative sentiment in the market.
• Investors might be cautious about the company's ability to address challenges like scale disadvantages and margin pressure, which could be contributing to the bearish trend in RGEN's stock price today.

12.01.2026 - RGEN Stock was down 5.1%

• The announcement of Repligen Corporation reporting its fourth quarter and full year 2025 financial results may have raised concerns among investors, leading to a bearish sentiment.
• Azzad Asset Management Inc. ADV reducing its stake in RGEN by 60.7% in Q3 and the significant insider selling of shares in the last three months could have contributed to the negative market movement.
• Despite the endorsement from Baron Health Care Fund for Repligen's AI-driven bioprocessing platform, market sentiment may have been influenced by the cautionary advice for investors to consider various perspectives and risks, potentially impacting the stock price negatively.

25.01.2026 - RGEN Stock was down 3.9%

• Despite Repligen's impressive Q4 2025 earnings beat and revenue growth, the stock experienced a significant bearish movement.
• The bearish trend can be attributed to the market's reaction to the company's 2026 guidance, which fell below analyst consensus, indicating a cautious outlook from management.
• Investors may have reacted negatively to the discrepancy between the strong quarterly performance and the lower-than-expected revenue forecast for the upcoming year, leading to the bearish movement in RGEN stock.
• The overall positive sentiment towards Repligen's growth momentum and strategic innovations, as well as the favorable analyst ratings, suggests that the bearish market movement today may present a potential buying opportunity for long-term investors eyeing the company's growth prospects.

24.01.2026 - RGEN Stock was up 1.1%

• Repligen (RGEN) saw significant positive movement in the market, likely influenced by favorable investor sentiment and expectations for the upcoming earnings release.
• Analysts forecast substantial year-over-year revenue growth for Repligen, suggesting a promising financial outlook.
• The recent acquisition of a stake by CenterBook Partners LP and increased activity from other institutional investors may have bolstered the optimistic market sentiment, indicating confidence in Repligen's future.
• Emphasis on the recovery of the bioprocessing industry, ongoing revenue growth, and margin expansion through new product offerings likely contributed to the positive market sentiment towards the company.

03.02.2026 - RGEN Stock was down 5.3%

• Repligen (RGEN) witnessed a 3.09% decline in shares attributed to a cautious outlook for 2026, despite posting robust Q4 2025 results, eliciting varied responses from investors.
• Analysts suggest that the stock may be overvalued based on its Price/Sales ratio compared to industry norms and the "Fair Ratio" according to Simply Wall St, potentially contributing to the downward trend.
• A reduction in Repligen's price target by Evercore ISI Group to $170 from $180 could have further dampened investor sentiment, although other analysts anticipate significant upside potential.
• Market behavior likely reflects investor worries about the company's revenue forecast, risks associated with biotech funding fluctuations, and concerns regarding customer concentration as mentioned in the provided guidance.

05.01.2026 - RGEN Stock was down 6.1%

• The bearish movement in RGEN's stock price could be attributed to significant insider selling activity by company executives and institutional investors reducing their holdings.
• Despite the positive long-term outlook, the near and mid-term sentiment appears weak, leading to a downside target of 13.3%.
• The mixed institutional investor activity, with some increasing and others decreasing their positions, might have added to the selling pressure on RGEN's stock.
• The overall market sentiment towards RGEN remains cautiously optimistic, as indicated by the "Moderate Buy" consensus rating from Wall Street analysts with an average price target of $179.62.

11.01.2026 - RGEN Stock was down 5.0%

• The anticipation of Repligen's fourth quarter and full year 2025 financial results might have caused uncertainty among investors, contributing to the bearish sentiment.
• Azzad Asset Management Inc. significantly reduced its stake in RGEN by 60.7%, possibly adding to the selling pressure and indicating reduced confidence from institutional investors.
• Baron Health Care Fund endorsed Repligen's AI-driven bioprocessing platform, but the market seemed more focused on recent insider selling and overall weak sentiment highlighted in technical analysis.
• An analysis reflecting a negative near and mid-term sentiment, suggesting a short setup and downside target, likely influenced traders to adopt a bearish position on RGEN. Monitoring price action is crucial for making tactical trading decisions.

21.10.2025 - RGEN Stock was up 5.5%

• The rise in RGEN's stock price is possibly a result of favorable investor sentiment towards the company's P/E ratio.
• Despite a slight decline in the previous month, the substantial increase in the stock price over the last year indicates promising long-term growth prospects, which may have attracted investors.
• The 0.65% increase in the current market session could also be influenced by general market positivity or specific industry trends benefiting biopharmaceutical firms like Repligen Inc.

04.02.2026 - RGEN Stock was up 6.1%

• Repligen's COO and CEO both had tax-withholding share dispositions, which could indicate a routine financial activity rather than a significant event impacting the company's fundamentals.
• Despite a recent drop in share price on February 27, analysts remain optimistic about Repligen, with a forecasted upside potential of around 45-47%.
• The mixed investor reactions to Repligen's strong Q4 2025 results and cautious 2026 guidance suggest uncertainty about the company's future performance, particularly regarding revenue and EPS projections.
• The recommendation to avoid investing in Repligen due to concerns about distribution channels, operating margins, and return on invested capital may have contributed to the bearish movement on February 27, but the overall bullish trend today could be attributed to the positive long-term outlook and potential growth opportunities in the bioprocessing industry.

12.02.2026 - RGEN Stock was down 5.2%

• The bearish movement in RGEN's stock today could be attributed to concerns about potential valuation risks due to its high P/E ratio of 138x, significantly above the industry average.
• Despite the positive financial performance and exceeding earnings expectations, the pressure faced by healthcare stocks after a weak February jobs report might have contributed to the downward movement in RGEN's stock price.
• The increased stake by institutional investors like Geneva Capital Management LLC and Schroder Investment Management Group could indicate a vote of confidence in the company's long-term prospects, potentially mitigating some of the short-term bearish sentiment.
• Investors may be reevaluating RGEN's valuation and growth prospects in light of mixed sentiment and the need to carefully analyze the company's financial numbers amidst market uncertainties.

31.09.2025 - RGEN Stock was up 5.0%

• Despite strong Q3 earnings, with revenue growth surpassing expectations, Repligen (RGEN) witnessed a stock dip possibly due to revised EPS guidance.
• The current bullish market trend for RGEN implies a reevaluation of the initial response to the earnings, indicating a perceived undervaluation of the stock.
• Positive surprises in both earnings and revenues for Q3 may have boosted investor confidence, leading to increased buying activity and a rise in stock price.
• The uptrend in RGEN today may stem from investors revisiting the company's performance and recognizing it as a more appealing investment opportunity, despite the initial setback.